Dr. Miel Sundararajan, MD

Dr. Sundararajan practices at Harborview Medical Center in Seattle, Washington, part of University of Washington.

Dr. Sundararajan's NPI, 1033503966, was assigned on March 28, 2015. Dr. Sundararajan graduated from Baylor College of Medicine in 2015. Dr. Sundararajan holds Washington license MD61174750.

Dr. Sundararajan's primary practice is Harborview Medical Center, at 325 9th Avenue, Seattle, WA 98104 in King County. The practice phone is (206) 744-9535.

Dr. Sundararajan's primary practice is Harborview Medical Center in Seattle, Washington, part of University of Washington. Dr. Sundararajan is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians. Dmand AI also links Dr. Sundararajan to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sundararajan practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Sundararajan's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Sundararajan is licensed in Washington.

CMS data shows 668 Medicare services from Dr. Sundararajan across 11 procedure codes in 2024, for 195 Medicare patients. Medicare paid $43,971 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 195 Medicare patients who saw Dr. Sundararajan in 2024. The largest group is 75 to 84, with 77 patients. 66% of them have high cholesterol, and 62% have high blood pressure. 21% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sundararajan's median patient age at 60, with 50% women.

In 2024, Dr. Sundararajan wrote 983 Medicare Part D claims for 204 patients. 62% of them were for generic drugs. CMS names the drug for 896 of them, across 21 drugs with 11 or more claims each, at $63,782 in total drug cost. In 2023, CMS named 549 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Sundararajan for performance year 2024, reported through an alternative payment model (APM). Dr. Sundararajan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 22 procedures of cataract surgery by Dr. Sundararajan, more than 47% of the clinicians it reports for that procedure.

CMS Open Payments shows 24 general payments to Dr. Sundararajan from 6 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 78% of the total. Genentech, Inc. paid the most, $11,777.

Dr. Sundararajan graduated from Baylor College of Medicine in 2015.